Responses to Other Students: Respond to at least 1 of your fellow classmates with at least a 250-word reply about their Primary Task Response regarding items you found to be compelling and enlightening. To help you with your discussion, please consider the following questions:
- What did you learn from your classmate’s posting?
- What additional questions do you have after reading the posting?
- What clarification do you need regarding the posting?
- What differences or similarities do you see between your posting and other classmates’ postings?
All sources should be cited using APA format. Grammar, spelling, punctuation, and format should be correct and professional.
Discussion Board Rubric
The Discussion Board Grading Rubric is a scoring tool that represents the performance expectations for the discussion. This Grading Rubric is divided into components that provide a clear description of what should be included within each component for the discussion. It is the road map that can help lead your discussion.
For assistance with your assignment, please use your textbook and all course resources.
POST TO READ
Dual-Agonist Peptide Therapy in Evidence-Based Health Promotion
Obesity and metabolic syndrome continue to significantly impact cardiovascular health, insulin sensitivity, and overall quality of life. Traditional lifestyle interventions remain foundational; however, physiologic adaptations such as increased hunger signaling and metabolic slowdown often limit sustained success. Recently, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, such as tirzepatide, have emerged as innovative peptide therapies demonstrating substantial weight reduction and metabolic improvement. Unlike single GLP-1 receptor agonists, dual agonists target complementary hormonal pathways, enhancing glycemic control and satiety.
PICOT Question:
In overweight or obese adults enrolled in a structured wellness program (P), how does the addition of weekly dual GIP/GLP-1 receptor agonist therapy (tirzepatide) (I) compared with lifestyle counseling alone (C) affect percent body weight reduction, HbA1c levels, and cardiometabolic risk markers (O) over 6 months (T)?
Population and Unique Healthcare Needs
The selected population includes overweight or obese adults participating in a health promotion program. This group commonly presents with insulin resistance, dyslipidemia, elevated inflammatory markers, and increased risk for cardiovascular disease. Many individuals experience repeated cycles of weight loss and regain due to biological adaptations that defend body weight.
Dual-agonist peptide therapy has demonstrated significant reductions in body weight and improved glycemic outcomes in both diabetic and non-diabetic populations (Jastreboff et al., 2022). Compared with earlier GLP-1 therapies, tirzepatide has shown greater average weight loss and improved cardiometabolic parameters, offering a promising adjunct to lifestyle modification. However, pharmacologic intervention alone does not ensure sustainable behavioral change, reinforcing the need for integration within a comprehensive wellness model.
Theoretical Framework
Nola Penders Health Promotion Model (HPM) was selected to guide this intervention. The HPM emphasizes self-efficacy, perceived benefits, and commitment to action as determinants of health behavior change. Within this model, tirzepatide may reduce physiologic hunger cues, thereby decreasing perceived barriers to dietary adherence. However, sustained success requires behavioral reinforcement, goal-setting, and active engagement in physical activity and nutrition strategies.
Theory-guided interventions strengthen patient adherence and long-term maintenance by addressing both biological and psychosocial determinants of health behavior (Whitehead et al., 2021). Applying the HPM ensures that dual-agonist therapy functions as a supportive tool within a broader health promotion strategy rather than a standalone solution.
Evaluation of Outcomes
Effectiveness would be evaluated through both objective clinical measures and patient-reported outcomes.
Quantitative measures:
- Percent total body weight loss
- Body mass index (BMI)
- HbA1c levels
- Fasting lipid panel
- Waist circumference
- Blood pressure
These biomarkers reflect cardiometabolic risk reduction and align with contemporary obesity management standards (American Diabetes Association [ADA], 2024).
Qualitative measures:
- Self-efficacy related to nutrition and exercise adherence
- Health-related quality of life scales
- Patient satisfaction
- Perceived barriers to sustained behavior change
Using both physiologic and psychosocial measures provides a comprehensive evaluation of the interventions effectiveness.
Conclusion
Dual GIP/GLP-1 receptor agonist therapy, such as tirzepatide, represents an innovative and evidence-based advancement in obesity management. When incorporated into a structured wellness program guided by the Health Promotion Model, this approach supports both physiologic appetite regulation and sustainable behavior change. Measuring both metabolic improvements and patient-centered outcomes ensures a holistic evaluation of effectiveness. This PICOT question establishes a strong foundation for further literature review and evidence-based project development.
References
American Diabetes Association. (2024). Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of care in diabetes2024. Diabetes Care, 47(Supplement_1), S128S139.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Rubino, D. M. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205216.
Whitehead, D., Taket, A., & Smith, P. (2021). Health promotion and health education: Advancing the concepts. Journal of Advanced Nursing, 77(5), 22232232.
Requirements: 300
Get this or a similar paper done in as fast as 4 hours, 24/7.
NB: We do not sell prewritten papers. All essays are written from scratch according to specific needs and instructions
Leave a Reply
You must be logged in to post a comment.